Early tissue responses to zoledronate, locally delivered by bone screw, into a compromised cancellous bone site: a pilot study

BMC Musculoskeletal Disorders

Philip Procter³  Antoine Alves²  Joerg Arnoldi¹ 

[1] Moraenenweg 6, 2544 Bettlach, Switzerland;Namsa-Biomatech, Chasse-sur-Rhone, France;School of Engineering & Design, Brunel University, Uxbridge, UK

关键词: Cellular events;    Early bone repair;    Zoledronic acid;    Bisphosphonates;    Osteointegration;    Screw;   

Others  :  1127826
DOI  :  10.1186/1471-2474-15-97

 received in 2013-08-23, accepted in 2014-03-12,  发布年份 2014

【 摘 要 】

Background

In fracture treatment, adequate fixation of implants is crucial to long-term clinical performance. Bisphosphonates (BP), potent inhibitors of osteoclastic bone resorption, are known to increase peri-implant bone mass and accelerate primary fixation. However, adverse effects are associated with systemic use of BPs. Thus, Zoledronic acid (ZOL) a potent BP was loaded on bone screws and evaluated in a local delivery model. Whilst mid- to long-term effects are already reported, early cellular events occurring at the implant/bone interface are not well described. The present study investigated early tissue responses to ZOL locally delivered, by bone screw, into a compromised cancellous bone site.

Methods

ZOL was immobilized on fibrinogen coated titanium screws. Using a bilateral approach, ZOL loaded test and non-loaded control screws were implanted into femoral condyle bone defects, created by an overdrilling technique. Histological analyses of the local tissue effects such as new bone formation and osteointegration were performed at days 1, 5 and 10.

Results

Histological evaluation of the five day ZOL group, demonstrated a higher osseous differentiation trend. At ten days an early influx of mesenchymal and osteoprogenitor cells was seen and a higher level of cellular proliferation and differentiation (p < 5%). In the ZOL group bone-to-screw contact and bone volume values within the defect tended to increase. Local drug release did not induce any adverse cellular effects.

Conclusion

This study indicates that local ZOL delivery into a compromised cancellous bone site actively supports peri-implant osteogenesis, positively affecting mesenchymal cells, at earlier time points than previously reported in the literature.

【 授权许可】

   
2014 Arnoldi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Mjoberg B: The theory of early loosening of hip prostheses. Orthopedics 1997, 20:1169-1175.
• [2]Navarro M, Michiardi A, Castano O, Planell JA: Biomaterials in orthopaedics. J R Soc Interface 2008, 5:1137-1158.
• [3]Hilding M, Ryd L, Toksvig-Larsen S, Aspenberg P: Clodronate prevents prosthetic migration: a randomized radiostereometric study of 50 total knee patients. Acta Orthop Scand 2000, 71:553-557.
• [4]Moroni A, Faldini C, Hoang-Kim A, Pegreffi F, Giannini S: Alendronate improves screw fixation in osteoporotic bone. J Bone Joint Surg Am 2007, 89:96-101.
• [5]Harding AK, Toksvig-Larsen S, Tagil M, WD A: A single dose zoledronic acid enhances pin fixation in high tibial osteotomy using the hemicallotasis technique. A double-blind placebo controlled randomized study in 46 patients. Bone 2010, 46:649-654.
• [6]Meraw SJ, Reeve CM: Qualitative analysis of peripheral peri-implant bone and influence of alendronate sodium on early bone regeneration. J Periodontol 1999, 70:1228-1233.
• [7]Venesmaa PK, Kroger HP, Miettinen HJ, Jurvelin JS, Suomalainen OT, Alhav EM: Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: a prospective randomized study. J Bone Miner Res 2001, 16:2126-2131.
• [8]Wilkinson JM, Stockley I, Peel NF, Hamer AJ, Elson RA, Barrington NA, Eastell R: Effect of pamidronate in preventing local bone loss after total hip arthroplasty: a randomized, double-blind, controlled trial. J Bone Miner Res 2001, 16:556-564.
• [9]Soininvaara TA, Jurvelin JS, Miettinen HJ, Suomalainen OT, Alhava EM, Kroger PJ: Effect of alendronate on periprosthetic bone loss after total knee arthroplasty: a one-year, randomized, controlled trial of 19 patients. Calcif Tissue Int 2002, 71:472-477.
• [10]Yoshinari M, Oda Y, Inoue T, Matsuzaka K, Shimono M: Bone response to calcium phosphate-coated and bisphosphonate-immobilized titanium implants. Biomaterials 2002, 23:2879-2885.
• [11]Little DG, Smith NC, Williams PR, Briody JN, Bilston LE, Smith EJ, Gardiner EM, Cowell CT: Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis. J Bone Miner Res 2003, 18:1300-1307.
• [12]Astrand J, Aspenberg P: Topical, single dose bisphosphonate treatment reduced bone resorption in a rat model for prosthetic loosening. J Orthop Res 2004, 22:244-249.
• [13]Bobyn JD, Hacking SA, Krygier JJ, Harvey EJ, Little DG, Tanzer M: Zoledronic acid causes enhancement of bone growth into porous implants. J Bone Joint Surg (Br) 2005, 87:416-420.
• [14]Peter B, Zambelli PY, Guicheux J, Pioletti DP: The effect of bisphosphonates and titanium particles on osteoblasts: an in vitro study. J Bone Joint Surg (Br) 2005, 87:1157-1163.
• [15]Wise LM, Waldman SD, Kasra M, Cheung R, Binnington A, Kandel RA, White LM, Grynpas MD: Effect of zoledronate on bone quality in the treatment of aseptic loosening of hip arthroplasty in the dog. Calcif Tissue Int 2005, 77:367-375.
• [16]Peter B, Gauthier O, Laib S, Bujoli B, Guicheux J, Janvier P, van Lenthe GH, Muller R, Zambelli PY, Bouler JM, Pioletti DP: Local delivery of bisphosphonate from coated orthopedic implants increases implants mechanical stability in osteoporotic rats. J Biomed Mater Res A 2006, 76:133-143.
• [17]Goodship AE, Blunn GW, Green J, Coathup MJ: Prevention of strain-related osteopenia in aseptic loosening of hip prostheses using perioperative bisphosphonate. J Orthop Res 2008, 26:693-703.
• [18]Stadelmann VA, Gauthier O, Terrier A, Bouler JM, Pioletti DP: Implants delivering bisphosphonate locally increase periprosthetic bone density in an osteoporotic sheep model. A pilot study. Eur Cell Mater 2008, 16:10-16.
• [19]Suratwala SJ, Cho SK, van Raalte JJ, Park SH, Seo SW, Chang SS, Gardner TR, Lee FY: Enhancement of periprosthetic bone quality with topical hydroxyapatite-bisphosphonate composite. J Bone Joint Surg Am 2008, 90:2189-2196.
• [20]Jakobsen T, Baas J, Kold S, Bechtold JE, Elmengaard B, Soballe K: Local bisphosphonate treatment increases fixation of hydroxyapatite-coated implants inserted with bone compaction. J Orthop Res 2009, 27:189-194.
• [21]Abtahi J, Tengvall P, Aspenberg P: A bisphosphonate-coating improves the fixation in metal implants in human bone. A randomized trial of dental implants. Bone 2012, 50:1148-1151.
• [22]Ruggiero SL, Mehrotra B: Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management. Annu Rev Med 2009, 60:85-96.
• [23]Schilcher J, Koeppen V, Ranstam J, Skripitz R, Michaëlsson K, Aspenberg P: Atypical femoral fractures are a separate entity, characterized by highly specific radiographic features. A comparison of 59 cases and 218 controls. Bone 2013, 52:389-392.
• [24]Aspenberg P: Bisphosphonates and implants: an overview. Acta Orthop 2009, 80:119-123.
• [25]Tengvall P, Skoglund B, Askendal A, Aspenberg P: Surface immobilized bisphosphonate improves stainless-steel screw fixation in rats. Biomaterials 2004, 25:2133-2138.
• [26]Wermelin K, Tengvall P, Aspenberg P: Surface-bound bisphosphonates enhance screw fixation in rats - increasing effect up to 8 weeks after insertion. Acta Orthop 2007, 78:385-392.
• [27]Wermelin K, Suska F, Tengvall P, Thomsen P, Aspenberg P: Stainless steel screws coated with bisphosphonates gave stronger fixation and more surrounding bone. Histomorphometry in rats. Bone 2008, 42:365-371.
• [28]Wermelin K, Aspenberg P, Linderback P, Tengvall P: Bisphosphonate coating on titanium screws increases mechanical fixation in rat tibia after two weeks. J Biomed Mater Res A 2008, 86:220-227.
• [29]Fleisch H: Bisphosphonates: mechanisms of action. Endocr Rev 1998, 19:80-100.
• [30]Peter B, Pioletti DP, Laib S, Bujoli B, Pilet P, Janvier P, Guicheux J, Zambelli PY, Bouler JM, Gauthier O: Calcium phosphate drug delivery system: influence of local zoledronate release on bone implant osteointegration. Bone 2005, 36:52-60.
• [31]Miettinen SS, Jaatinen J, Pelttari A, Lappalainen R, Monkkonen J, Venesmaa PK, Kroger HP: Effect of locally administered zoledronic acid on injury-induced intramembranous bone regeneration and osseointegration of a titanium implant in rats. J Orthop Sci 2009, 14:431-436.
• [32]Hoshikawa A, Fukui N: Quantitative analysis of the resorption and osteo-conduction process of a calcium phosphate cement and its mechanical effect for screw fixation. Biomaterials 2003, 24:4967-4975.
• [33]Abtahi J, Tengvall P, Aspenberg P: Bisphosphonate coating might improve fixation of dental implants in the maxilla. A pilot study. Int J Oral Maxillofac Surg 2010, 39:673-677.
• [34]Donath K, Breuner G: A method for the study of undecalcified bones and teeth with attached soft tissues. The Sage-Schliff (sawing and grinding) technique. J Oral Pathol 1982, 11:318-326.
• [35]Gao Y, Zou S, Liu X, Bao C, Hu J: The effect of surface immobilized bisphosphonates on the fixation of hydroxyapatite-coated titanium implants in ovariectomized rats. Biomaterials 2009, 30:1790-6.
• [36]Andersson T, Agholme F, Aspenberg P, Tengvall P: Surface immobilized zoledronate improves screw fixation in rat bone: a new method for the coating of metal implants. J Mater Sci 2010, 21:3029-3037.
• [37]Castaneda S, Calvo E, Largo R, Gonzalez-Gonzalez R, de la Piedra C, Diaz-Curiel M, Herrero-Beaumont G: Characterization of a new experimental model of osteoporosis in rabbits. J Bone Miner Metab 2008, 26:53-59.
• [38]Peter B: Orthopedic implants used as drug delivery systems: numerical, in vitro and in vivo studies [SECTION DE PHYSIQUE]. Lausanne: École Polytechnique Fédérale de Lausanne; 2004.
• [39]Lin JH, Russell G, Gertz B: Pharmacokinetics of alendronate: an overview. Int J Clin Pract Suppl 1999, 101:18-26.
• [40]Hoffman A, Stepensky D, Ezra A, Van Gelder JM, Golomb G: Mode of administration-dependent pharmacokinetics of bisphosphonates and bioavailability determination. Int J Pharm 2001, 220:1-11.
• [41]Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, Schran H, Seaman J, Skerjanec A: Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002, 42:1228-1236.
• [42]Ogura Y, Gonsho A, Cyong JC, Orimo H: Clinical trial of risedronate in Japanese volunteers: a study on the effects of timing of dosing on absorption. J Bone Miner Metab 2004, 22:120-126.
• [43]Schindeler A, Little DG: Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro. Biochem Biophys Res Commun 2005, 338:710-716.
• [44]Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ: Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 2008, 42:848-860.
• [45]Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH: Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006, 38:617-627.
• [46]Anderson JM: Biological responses to materials. Annu Rev Mater Res 2001, 31:81-110.
• [47]Cardemil C, Omar OM, Norlindh B, Wexell CL, Thomsen P: The effects of a systemic single dose of zoledronic acid on post-implantation bone remodelling and inflammation in an ovariectomized rat model. Biomaterials 2013, 34:1546-1561.
• [48]Slaets E, Carmeliet G, Naert I, Duyck J: Early trabecular bone healing around titanium implants: a histologic study in rabbits. J Periodontol 2007, 78:510-517.